BIOMARIN PHARMACEUTICAL INC Net Income (Loss) Available to Common Stockholders, Diluted
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Net Income (Loss) Available to Common Stockholders, Diluted of $44.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $44.76M, a 81.53% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $107.36M, a 42.75% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$44.74M, a 135.29% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$30.74M, a 128.49% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for fiscal 2025 was $356.24M, a 17.95% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for fiscal 2024 was $434.19M, a 158.99% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for fiscal 2023 was $167.65M, a 18.43% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, diluted for fiscal 2022 was $141.56M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.76M 10-Q · filed 2026-08-06 | $150.29M 10-Q · filed 2026-08-06 | $107.39M derived: sum of 3 quarters · filed 2026-08-06 | $76.64M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $107.36M 10-Q · filed 2026-05-05 | $62.62M derived: sum of 2 quarters · filed 2026-05-05 | $31.88M derived: sum of 3 quarters · filed 2026-05-05 | $274.24M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$44.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$75.48M derived: sum of 2 quarters · filed 2026-02-26 | $166.88M derived: sum of 3 quarters · filed 2026-08-06 | $356.24M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$30.74M 10-Q · filed 2025-10-28 | $211.62M derived: sum of 2 quarters · filed 2026-08-06 | $400.97M 10-Q · filed 2025-10-28 | $525.91M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $242.37M 10-Q · filed 2026-08-06 | $429.88M 10-Q · filed 2026-08-06 | $556.66M derived: sum of 3 quarters · filed 2026-08-06 | $664.57M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $187.52M 10-Q · filed 2026-05-05 | $314.29M derived: sum of 2 quarters · filed 2026-05-05 | $422.21M derived: sum of 3 quarters · filed 2026-05-05 | $532.15M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $126.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $234.69M derived: sum of 2 quarters · filed 2026-02-26 | $344.63M derived: sum of 3 quarters · filed 2026-02-26 | $434.19M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $107.91M 10-Q · filed 2025-10-28 | $217.85M derived: sum of 2 quarters · filed 2025-10-28 | $307.41M 10-Q · filed 2025-10-28 | $326.85M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $109.94M 10-Q · filed 2025-08-05 | $201.37M 10-Q · filed 2025-08-05 | $218.94M derived: sum of 3 quarters · filed 2026-02-26 | $259.32M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $91.43M 10-Q · filed 2025-05-02 | $109.00M derived: sum of 2 quarters · filed 2026-02-26 | $149.37M derived: sum of 3 quarters · filed 2026-02-26 | $206.35M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $17.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.94M derived: sum of 2 quarters · filed 2026-02-26 | $114.92M derived: sum of 3 quarters · filed 2026-02-26 | $167.65M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $40.38M 10-Q · filed 2024-10-31 | $97.36M derived: sum of 2 quarters · filed 2024-10-31 | $150.08M 10-Q · filed 2024-10-31 | $146.09M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-06-30 | $56.98M 10-Q · filed 2024-08-05 | $108.77M 10-Q · filed 2024-08-05 | $105.71M derived: sum of 3 quarters · filed 2025-02-24 | $99.06M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-03-31 | $51.79M 10-Q · filed 2024-04-26 | $48.73M derived: sum of 2 quarters · filed 2025-02-24 | $42.08M derived: sum of 3 quarters · filed 2025-02-24 | $69.75M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2022-12-31 | -$3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$9.71M derived: sum of 2 quarters · filed 2025-02-24 | $17.96M derived: sum of 3 quarters · filed 2025-02-24 | $141.56M 10-K · filed 2025-02-24 | |||
| 2022-09-30 | -$6.65M 10-Q · filed 2023-11-02 | $21.01M derived: sum of 2 quarters · filed 2023-11-02 | $144.62M 10-Q · filed 2023-11-02 | $86.67M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $27.66M 10-Q · filed 2023-08-02 | $150.33M 10-Q · filed 2023-08-02 | $93.33M derived: sum of 3 quarters · filed 2023-08-02 | $56.83M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $123.56M 10-Q · filed 2023-04-28 | $65.66M derived: sum of 2 quarters · filed 2023-04-28 | $29.17M derived: sum of 3 quarters · filed 2023-04-28 | $42.11M derived: sum of 4 quarters · filed 2023-04-28 | |||
| 2021-12-31 | -$57.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$94.39M derived: sum of 2 quarters · filed 2023-02-27 | -$81.45M derived: sum of 3 quarters · filed 2023-02-27 | -$64.08M 10-K · filed 2023-02-27 | |||
| 2021-09-30 | -$36.49M 10-Q · filed 2022-10-28 | -$23.55M derived: sum of 2 quarters · filed 2022-10-28 | -$6.18M 10-Q · filed 2022-10-28 | $826.00K derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | $12.94M 10-Q · filed 2022-08-04 | $30.31M 10-Q · filed 2022-08-04 | $37.32M derived: sum of 3 quarters · filed 2023-02-27 | $829.19M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | $17.37M 10-Q · filed 2022-04-29 | $24.38M derived: sum of 2 quarters · filed 2023-02-27 | $816.25M derived: sum of 3 quarters · filed 2023-02-27 | $787.07M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $798.88M derived: sum of 2 quarters · filed 2023-02-27 | $769.70M derived: sum of 3 quarters · filed 2023-02-27 | $862.34M 10-K · filed 2023-02-27 | $867.41M 10-K · filed 2021-02-26 | ||
| 2020-09-30 | $791.87M 10-Q · filed 2021-10-29 | $762.69M derived: sum of 2 quarters · filed 2021-10-29 | $855.33M 10-Q · filed 2021-10-29 | $860.03M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | -$29.18M 10-Q · filed 2021-07-30 | $52.20M 10-Q · filed 2021-07-30 | $68.16M derived: sum of 3 quarters · filed 2022-02-25 | $124.13M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $82.32M 10-Q · filed 2021-04-30 | $97.34M derived: sum of 2 quarters · filed 2022-02-25 | $153.31M derived: sum of 3 quarters · filed 2022-02-25 | ||||
| 2019-12-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $71.00M derived: sum of 2 quarters · filed 2022-02-25 | -$23.85M 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $55.97M 10-Q · filed 2020-11-06 | -$38.87M 10-Q · filed 2020-11-06 | |||||
| 2019-03-31 | -$56.47M 10-Q · filed 2020-05-01 | -$60.83M derived: sum of 2 quarters · filed 2021-02-26 | -$73.45M derived: sum of 3 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | -$4.36M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | -$16.98M derived: sum of 2 quarters · filed 2021-02-26 | -$77.92M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$12.62M 10-Q/A · filed 2019-11-04 | -$73.56M 10-Q/A · filed 2019-11-04 | |||||
| 2018-03-31 | -$45.47M 10-Q · filed 2019-04-29 | -$96.86M derived: sum of 2 quarters · filed 2020-02-27 | -$109.39M derived: sum of 3 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | -$51.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$63.92M derived: sum of 2 quarters · filed 2020-02-27 | -$117.04M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | -$12.53M 10-Q · filed 2017-10-31 | -$65.65M 10-Q · filed 2017-10-31 | |||||
| 2017-03-31 | -$16.29M 10-Q · filed 2018-04-27 | -$108.44M derived: sum of 2 quarters · filed 2019-02-28 | -$145.87M derived: sum of 3 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | -$92.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$129.58M derived: sum of 2 quarters · filed 2019-02-28 | -$633.39M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$37.42M 10-Q · filed 2017-10-31 | -$42.80M 10-Q · filed 2016-11-03 | -$541.24M 10-Q · filed 2017-10-31 | -$553.25M 10-Q · filed 2016-11-03 | |||
| 2015-12-31 | $68.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$27.29M derived: sum of 2 quarters · filed 2018-02-26 | -$109.28M derived: sum of 3 quarters · filed 2018-02-26 | -$171.80M 10-K · filed 2018-02-26 | |||
| 2015-09-30 | -$95.91M 10-Q · filed 2016-11-03 | -$177.90M derived: sum of 2 quarters · filed 2016-11-03 | -$240.42M 10-Q · filed 2016-11-03 | -$315.19M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | -$81.99M 10-Q · filed 2015-08-05 | -$149.49M 10-Q · filed 2015-08-05 | -$219.29M derived: sum of 3 quarters · filed 2017-02-27 | -$211.69M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | -$67.50M 10-Q · filed 2015-05-05 | -$137.30M derived: sum of 2 quarters · filed 2017-02-27 | -$129.70M derived: sum of 3 quarters · filed 2017-02-27 | -$163.71M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | -$69.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$62.20M derived: sum of 2 quarters · filed 2017-02-27 | -$96.20M derived: sum of 3 quarters · filed 2017-02-27 | -$133.97M 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $7.60M 10-Q · filed 2015-11-02 | -$26.41M derived: sum of 2 quarters · filed 2015-11-02 | -$64.17M 10-Q · filed 2015-11-02 | ||||
| 2014-06-30 | -$34.01M 10-Q · filed 2015-08-05 | -$72.36M 10-Q · filed 2015-08-05 | |||||
| 2014-03-31 | -$38.49M 10-Q · filed 2015-05-05 | ||||||
| 2013-09-30 | -$53.02M 10-Q · filed 2014-10-28 | -$75.37M derived: sum of 2 quarters · filed 2014-10-28 | -$114.36M 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | -$22.35M 10-Q · filed 2014-07-31 | -$22.81M 10-Q · filed 2013-07-29 | -$61.34M 10-Q · filed 2014-07-31 | ||||
| 2013-03-31 | -$39.81M 10-Q · filed 2014-05-02 | ||||||
| 2012-12-31 | -$114.35M 10-K · filed 2013-02-26 | ||||||
| 2012-06-30 | -$32.01M 10-Q · filed 2013-07-29 | -$55.98M 10-Q · filed 2013-07-29 | -$82.71M derived: sum of 3 quarters · filed 2013-07-29 | -$100.37M derived: sum of 4 quarters · filed 2013-07-29 | |||
| 2012-03-31 | -$23.97M 10-Q · filed 2012-04-30 | -$50.71M derived: sum of 2 quarters · filed 2013-02-26 | -$68.36M derived: sum of 3 quarters · filed 2013-02-26 | -$73.44M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-12-31 | -$26.73M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$44.39M derived: sum of 2 quarters · filed 2013-02-26 | -$49.47M derived: sum of 3 quarters · filed 2013-02-26 | -$53.84M 10-K · filed 2013-02-26 | |||
| 2011-09-30 | -$17.65M 10-Q · filed 2011-10-31 | -$22.73M derived: sum of 2 quarters · filed 2011-10-31 | -$27.10M 10-Q · filed 2011-10-31 | -$36.95M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-06-30 | -$5.08M 10-Q · filed 2011-08-01 | -$9.45M 10-Q · filed 2011-08-01 | -$19.30M derived: sum of 3 quarters · filed 2013-02-26 | $201.05M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-03-31 | -$4.53M 10-Q · filed 2012-04-30 | -$14.22M derived: sum of 2 quarters · filed 2013-02-26 | $206.13M derived: sum of 3 quarters · filed 2013-02-26 | $205.32M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | -$9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $210.65M derived: sum of 2 quarters · filed 2013-02-26 | $209.85M derived: sum of 3 quarters · filed 2013-02-26 | $217.34M 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $220.34M 10-Q · filed 2011-10-31 | $219.54M derived: sum of 2 quarters · filed 2011-10-31 | $227.04M 10-Q · filed 2011-10-31 | ||||
| 2010-06-30 | -$801.00K 10-Q · filed 2011-08-01 | $625.00K 10-Q · filed 2011-08-01 | |||||
| 2009-12-31 | -$488.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |